Sex and Race Differences in Cardiac Sarcoidosis Presentation, Treatment and Outcomes.
J Card Fail
; 29(8): 1135-1145, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37062472
ABSTRACT
BACKGROUND:
Although sex- and race-based patterns have been described in the extracardiac organ involvement of sarcoidosis, cardiac sarcoidosis (CS)-specific studies are lacking.METHODS:
We studied CS presentation, treatment and outcomes based on sex and race in a tertiary-center cohort. Multivariable adjusted Cox proportional hazards and survival analyses were performed for primary composite outcomes (left ventricular assist device, heart transplantation, all-cause death) and for secondary outcomes (ventricular arrhythmia and all-cause death.RESULTS:
We identified 252 patients with CS (108 female, 109 Black). At presentation with CS, females vs males (Pâ¯=â¯0.001) and Black vs White individuals (Pâ¯=â¯0.001) more commonly had symptomatic heart failure (HF), with HF most common in Black females (ANOVA P < 0.001). Treatment differences included more corticosteroid use (90% vs 79%; Pâ¯=â¯0.020), higher 1-year prednisone dosage (13 vs 10 mg; Pâ¯=â¯0.003) and less frequent early steroid-sparing agent use in males (29% vs 40%; Pâ¯=â¯0.05). Black participants more frequently received a steroid-sparing agent (75% vs 60%; Pâ¯=â¯0.023). Composite outcome-free survival did not differ by sex or race. Male sex had an adjusted hazard ratio of 2.34 (95% CI 1.13, 4.80; Pâ¯=â¯0.021) for ventricular arrhythmia.CONCLUSION:
CS course may differ by sex and race and may contribute to distinct clinical CS phenotypes.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sarcoidosis
/
Heart Failure
/
Cardiomyopathies
/
Myocarditis
Type of study:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspects:
Determinantes_sociais_saude
Limits:
Female
/
Humans
/
Male
Language:
En
Journal:
J Card Fail
Journal subject:
CARDIOLOGIA
Year:
2023
Document type:
Article